(TOP (S (NP (CD Two) (JJ major) (NN drug) (NNS companies)) (VP (VBD posted) (NP (JJ strong) (JJ third-quarter) (NNS earnings)) (, ,) (PP (IN in) (NP (NP (NN line)) (PP (IN with) (NP (NP (NP (NNS profits)) (VP (ADVP (RB already)) (VBN reported) (PP (IN by) (NP (NN industry) (NNS leaders))))) (CC and) (NP (NP (NNS analysts) (POS ')) (NNS expectations))))))) (. .)) )
(TOP (S (CC But) (NP (NP (NNP Pfizer) (NNP Inc.)) (, ,) (VP (VBN based) (PP (IN in) (NP (location (NNP New) (NNP York))))) (, ,)) (VP (VBD reported) (NP (JJ flat) (NNS earnings))) (. .)) )
(TOP (S (NP (NP (NNP Schering-Plough) (NNP Corp.)) (, ,) (VP (VBN based) (PP (IN in) (NP (NP (location (NNP Madison))) (, ,) (NP (NNP N.J.))))) (, ,)) (VP (VBD reported) (NP (NP (DT a) (ADJP (percentage (CD 21) (NN %))) (NN rise)) (PP (IN in) (NP (NNS earnings)))) (SBAR (IN as) (S (NP (NP (organization (NNP American) (NNP Home) (NNPS Products) (NNP Corp.))) (PP (IN of) (NP (location (NNP New) (NNP York))))) (VP (VBD posted) (NP (NP (DT an) (ADJP (percentage (CD 11) (NN %))) (NN increase)) (PP (IN in) (NP (NN net)))))))) (. .)) )
(TOP (S (NP (organization (NNP American) (NNP Home) (NNPS Products) (NNP American) (NNP Home) (NNPS Products))) (VP (VBD said) (SBAR (S (NP (NP (NNS sales) (CC and) (NNS earnings)) (PP (IN for) (NP (NP (DT the) (date (JJ third) (NN quarter))) (CC and) (NP (CD nine) (NNS months))))) (VP (AUX were) (PP (IN at) (NP (JJ record) (NNS levels))))))) (. .)) )
(TOP (S (NP (NP (NNS Sales)) (PP (IN for) (NP (DT the) (date (JJ third) (NN quarter))))) (VP (VBD increased) (NP (percentage (CD 6.5) (NN %))) (PP (TO to) (NP (QP (money ($ $) (CD 1.51) (CD billion))))) (PP (IN from) (NP (QP (money ($ $) (CD 1.42) (CD billion)))))) (. .)) )
(TOP (S (NP (NP (NNS Sales)) (PP (IN of) (NP (NN health-care) (NNS products)))) (VP (VBD increased) (NP (percentage (CD 6) (NN %))) (PP (IN in) (NP (DT the) (date (JJ third) (NN quarter)))) (, ,) (VP (VBN based) (PP (IN in) (NP (NP (NN part)) (PP (IN on) (NP (NP (NP (JJ strong) (NNS sales)) (PP (IN of) (NP (NP (NN prescription) (NNS drugs)) (PP (JJ such) (IN as) (NP (NP (NNP Premarin)) (, ,) (NP (DT an) (NN estrogen-replacement) (NN drug)) (, ,)))))) (CC and) (NP (NP (NNS sales)) (PP (IN of) (NP (NP (DT the) (NN company) (POS 's)) (NN infant) (NN formula)))))))))) (. .)) )
(TOP (S (NP (organization (NNP American) (NNP Home) (NNPS Products))) (VP (VBD said) (SBAR (S (NP (JJ net) (NN income)) (VP (VBD benefited) (PP (IN from) (NP (NP (DT a) (`` `) (`` `) (JJR lower) (JJ effective) (NN tax) (NN rate) (, ,) ('' ')) ('' ') (VP (VBG reflecting) (NP (NP (NP (DT a) (NN reduction)) (PP (IN of) (NP (JJ foreign) (NN tax) (NNS rates)))) (, ,) (CC and) (NP (NP (JJ additional) (NNS operations)) (PP (IN in) (NP (location (NNP Puerto) (NNP Rico))))))))))))) (. .)) )
(TOP (S (NP (NN Net)) (ADVP (RB also)) (VP (AUX was) (VP (VBN aided) (PP (IN by) (NP (NP (DT a) (NN gain)) (PP (IN on) (NP (NP (DT the) (NN sale)) (PP (IN of) (NP (NP (NP (DT the) (NN company) (POS 's)) (NN equity) (NNS interests)) (PP (IN in) (NP (location (NNP South) (NNP Africa)))))))) (ADJP (JJ effective) (NP (NNP Sept.) (CD 1))))))) (. .)) )
(TOP (S (PP (IN In) (NP (organization (NNP New) (NNP York) (NNP Stock) (NNP Exchange)) (JJ composite) (NN trading))) (NP (date (NN yesterday))) (, ,) (NP (organization (NNP American) (NNP Home) (NNPS Products))) (VP (VBD closed) (PP (IN at) (NP (NP (money ($ $) (CD 102.25))) (NP (DT a) (NN share)))) (, ,) (ADVP (RB down) (NP (money (CD 75) (NNS cents))))) (. .)) )
(TOP (S (NP (NNP Pfizer) (NNP Pfizer)) (VP (VBD said) (SBAR (S (NP (JJ third-quarter) (NNS sales)) (VP (VBD increased) (NP (percentage (CD 4) (NN %))) (PP (TO to) (NP (QP (money ($ $) (CD 1.44) (CD billion))))) (PP (IN from) (NP (QP (money ($ $) (CD 1.38) (CD billion))))))))) (. .)) )
(TOP (S (NP (DT The) (NN company)) (VP (VBD said) (SBAR (S (NP (JJ net) (NN income)) (VP (AUX was) (ADJP (JJ flat)) (PP (IN because) (IN of) (NP (NP (NP (NN investment)) (PP (IN in) (NP (NN research) (CC and) (NN development)))) (CC and) (NP (NP (NNS costs)) (ADJP (JJ related) (PP (TO to) (NP (NP (NNS launches)) (PP (IN of) (NP (JJ several) (NNS products))))))))))))) (. .)) )
(TOP (S (NP (DT The) (NN company)) (VP (VBD said) (SBAR (S (NP (NP (DT the) (NN dollar) (POS 's)) (JJ continued) (NN strengthening)) (VP (VBD reduced) (NP (JJ world-wide) (NNS sales) (NN growth)) (PP (IN by) (NP (CD three) (NN percentage) (NNS points))))))) (. .)) )
(TOP (S (NP (organization (NNP Pfizer))) (VP (VBD posted) (NP (NP (PRP$ its) (JJS largest) (NNS gains)) (PP (IN in) (NP (NP (NP (NN healthcare) (NNS sales)) (, ,) (ADVP (RB up) (NP (percentage (CD 3) (NN %)))) (, ,)) (CC and) (NP (NP (NN consumer) (NNS products)) (, ,) (ADVP (RB up) (NP (percentage (CD 23) (NN %))))))))) (. .)) )
(TOP (S (S (NP (NP (NNS Sales)) (PP (IN by) (NP (DT the) (NN specialty) (NNS chemicals) (CC and) (NNS materials) (NN science) (NNS segments)))) (VP (AUX were) (ADJP (JJ flat)))) (, ,) (CC and) (S (NP (NP (NNS sales)) (PP (IN by) (NP (DT the) (NN agriculture) (NN segment)))) (VP (VBD declined) (NP (percentage (CD 5) (NN %))))) (. .)) )
(TOP (S (PP (IN In) (NP (DT the) (JJ health-care) (NN segment))) (, ,) (S (NP (JJ pharmaceutical) (NNS sales)) (VP (VBD increased) (NP (percentage (CD 4) (NN %))))) (CC and) (S (NP (NP (NNS sales)) (PP (IN of) (NP (NN hospital) (NNS products)))) (VP (VBD increased) (NP (percentage (CD 1) (NN %))))) (. .)) )
(TOP (S (PP (IN During) (NP (DT the) (NN quarter))) (, ,) (NP (organization (NNP Pfizer))) (VP (VBD received) (NP (NP (JJ federal) (NN approval)) (PP (IN of) (NP (NP (NP (NNP Procardia) (NNP XL)) (, ,) (NP (NP (DT a) (NN calcium) (NN channel) (NN blocker)) (VP (VBN approved) (PP (IN for) (NP (DT both) (NN angina) (CC and) (NN hypertension))))) (, ,)) (CC and) (NP (NP (NNP Monorail) (NNP Piccolino)) (, ,) (VP (VBN used) (S (VP (TO to) (VP (VB open) (NP (VBN obstructed) (JJ coronary) (NNS arteries))))))))))) (. .)) )
(TOP (S (PP (IN In) (NP (organization (NNP New) (NNP York) (NNP Stock) (NNP Exchange)) (JJ composite) (NN trading))) (NP (date (NN yesterday))) (, ,) (NP (organization (NNP Pfizer))) (VP (VBD closed) (PP (IN at) (NP (NP (money ($ $) (CD 67.75))) (NP (DT a) (NN share)))) (, ,) (ADVP (RB up) (NP (money (CD 75) (NNS cents))))) (. .)) )
(TOP (S (NP (NNP Schering-Plough) (NNP Schering-Plough)) (VP (VBD said) (SBAR (S (NP (NNS sales)) (VP (VBD gained) (NP (percentage (CD 2.7) (NN %))) (PP (TO to) (NP (QP (money ($ $) (CD 743.7) (CD million))))) (PP (IN from) (NP (QP (money ($ $) (CD 724.4) (CD million))))))))) (. .)) )
(TOP (S (PP (IN In) (NP (DT the) (NN period))) (, ,) (NP (DT the) (NN company)) (VP (VP (VBD completed) (NP (NP (DT the) (NN sale)) (PP (IN of) (NP (PRP$ its) (JJ European) (NNS cosmetics) (NNS businesses))))) (, ,) (VP (VBD sold) (NP (NP (DT a) (NN majority) (NN interest)) (PP (IN in) (NP (PRP$ its) (JJ Brazilian) (NN affiliate))))) (, ,) (CC and) (VP (VBD announced) (NP (NP (DT the) (NN reorganization)) (PP (IN of) (NP (PRP$ its) (JJ over-the-counter) (NN drug) (NNS businesses))) (PP (IN into) (NP (NP (DT a) (JJ new) (NN unit)) (, ,) (NP (organization (NNP Schering-Plough) (NNP Health) (NNP Care) (NNPS Products)))))))) (. .)) )
(TOP (S (NP (DT These) (NNS actions)) (VP (AUX did) (RB n't) (VP (VB affect) (NP (NNS results)) (SBAR (IN because) (S (NP (NP (DT the) (NN gain)) (PP (IN on) (NP (NP (DT the) (NN sale)) (PP (IN of) (NP (DT the) (NNP European) (NNS cosmetics) (NNS businesses)))))) (VP (AUX was) (VP (VBN offset) (PP (IN by) (NP (NP (NNS provisions)) (VP (VBG relating) (PP (TO to) (NP (DT the) (NX (NX (location (NNP Brazil)) (NN divestiture)) (CC and) (NX (NN drug) (NN restructuring)))))))))))))) (. .)) )
(TOP (S (NP (NNP U.S.) (JJ pharmaceutical) (NNS sales)) (VP (VBD rose) (NP (percentage (CD 15) (NN %))) (, ,) (S (VP (VBN led) (PP (IN by) (NP (NP (NN allergy) (, ,) (NN asthma) (CC and) (JJ cold) (NNS products)) (: ;) (NP (JJ dermatological) (NNS products)) (: ;) (NP (NP (NNS anti-infectives)) (CC and) (NP (JJ anti-cancer) (NNS products))) (: ;) (CC and) (NP (JJ cardiovascular) (NNS products))))))) (. .)) )
(TOP (S (NP (JJ World-wide) (NN consumer) (NN product) (NNS sales)) (VP (VBD declined) (NP (percentage (CD 12) (NN %))) (, ,) (PP (ADVP (RB primarily)) (IN because) (IN of) (NP (DT the) (JJ European) (NNS cosmetics) (NN sale)))) (. .)) )
(TOP (S (NP (NP (ADJP (RB Significantly) (JJR lower)) (NNS sales)) (PP (IN of) (NP (`` `) (NNP Stay) (NNP Trim) ('' ') (NN diet) (NNS aids)))) (ADVP (RB also)) (VP (AUX were) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (DT the) (NN drop))))) (. .)) )
(TOP (S (NP (DT The) (NNP Maybelline) (NN beauty) (NN product) (NN line)) (VP (AUX had) (NP (JJR higher) (NNS sales)) (PP (VBG following) (NP (DT a) (JJ sluggish) (JJ first) (NN half)))) (. .)) )
(TOP (S (PP (IN In) (NP (NNP Big) (NNP Board) (JJ composite) (NN trading))) (, ,) (NP (organization (NNP Schering-Plough)) (NNS shares)) (VP (VBD fell) (NP (money (CD 75) (NNS cents))) (S (VP (TO to) (VP (VB close) (PP (IN at) (NP ($ $) (CD 74.125))))))) (. .)) )
